Description
EXERCISE THE FOURTH AND FINAL OPTION YEAR FOR LATANOPROST OPHTHALMIC SOLUTION CONTRACT 36E79722D0011 WITH SANDOZ, INC. WITH NO PRICE CHANGES.
Base award description: NEW AWARD FOR LATANOPROST OPHTHALMIC SOLUTION WITH SANDOZ, INC. PERIOD OF PERFORMANCE IS 03/21/2022 TO 03/20/2023 WITH FOUR 1-YEAR OPTIONS.
Modification chain · 12 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2022-01-26+$0= $0
- Mod P000012022-12-22+$0= $0
- Mod P000022023-03-14+$0= $0
- Mod P000032023-04-14+$0= $0
- Mod P000042024-02-02+$0= $0
- Mod P000052024-02-22+$0= $0
- Mod P000062024-02-22+$0= $0
- Mod P000072024-02-22+$0= $0
- Mod P000082025-01-03+$0= $0
- Mod P000092025-02-20+$0= $0
- Mod P000102026-01-07+$0= $0
- Mod P000112026-03-03+$0= $0
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2022-01-26 | +$0 | $0 | NEW AWARD FOR LATANOPROST OPHTHALMIC SOLUTION WITH SANDOZ, INC. PERIOD OF PERFORMANCE IS 03/21/2022 TO 03/20/2… |
| Mod P00001· ADD SUBCONTRACTING PLAN | 2022-12-22 | +$0 | $0 | INCORPORATE 2023 SUBCONTRACTING PLAN |
| Mod P00002· EXERCISE AN OPTION | 2023-03-14 | +$0 | $0 | EXERCISE OPTION YEAR 1 WITH SANDOZ FOR LATANOPROST OPHTHALMIC SOLUTION WITH PRICE CHANGES FOR ONE LINE ITEM. O… |
| Mod P00003· OTHER ADMINISTRATIVE ACTION | 2023-04-14 | +$0 | $0 | INCORPORATE UPDATED DSCSA LANGUAGE AND REQUIREMENTS INTO VA NATIONAL CONTRACT 36E79722D0011. |
| Mod P00004· ADD SUBCONTRACTING PLAN | 2024-02-02 | +$0 | $0 | INCORPORATE SANDOZ, INC. 2024 SUBK PLAN INTO CONTRACT. |
| Mod P00005· EXERCISE AN OPTION | 2024-02-22 | +$0 | $0 | EXERCISE THE SECOND OPTION YEAR FOR LATANOPROST OPHTHALMIC SOLUTION CONTRACT 36E79722D0011 WITH SANDOZ, INC. W… |
| Mod P00006· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2024-02-22 | +$0 | $0 | UPDATE TO COST RECOVERY FEE (CRF) AND SUBMISSION OF QUARTERLY SALES REPORTS 36E79722D0011, SANDOZ, INC. FOR LA… |
| Mod P00007· OTHER ADMINISTRATIVE ACTION | 2024-02-22 | +$0 | $0 | CHANGE SANDOZ, INC. POC FROM EVELYN BERGMAN TO ERIC SHINN. |
| Mod P00008· ADD SUBCONTRACTING PLAN | 2025-01-03 | +$0 | $0 | INCORPORATE SANDOZ'S 2025 SUBK PLAN INTO CONTRACT. PLAN EFFECTIVE 1/3/2025 - 12/31/2025. |
| Mod P00009· EXERCISE AN OPTION | 2025-02-20 | +$0 | $0 | EXERCISE THE THIRD OPTION YEAR FOR LATANOPROST OPHTHALMIC SOLUTION CONTRACT 36E79722D0011 WITH SANDOZ, INC. WI… |
| Mod P00010· ADD SUBCONTRACTING PLAN | 2026-01-07 | +$0 | $0 | INCORPORATE 2026 SMALL BUSINESS SUBCONTRACTING PLAN INTO CONTRACT. |
| Mod P00011· EXERCISE AN OPTION | 2026-03-03 | +$0 | $0 | EXERCISE THE FOURTH AND FINAL OPTION YEAR FOR LATANOPROST OPHTHALMIC SOLUTION CONTRACT 36E79722D0011 WITH SAND… |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI ETJGHMFH1MT5)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36F79723D0187 | NAC FEDERAL SUPPLY SCHEDULE (36F797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2023 |
| 36E79723D0005 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2023 |
| 36E79723D0001 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2023 |
| 36E79722D0033 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2022 |
| 36E79722D0016 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2022 |
| 36E79721D0010 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2021 |
Other recipients under 6505 from NAC PHARMACEUTICALS (36E797) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36E79726A0025 | CHIESI USA INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0024 | NEUROTECH PHARMACEUTICALS, INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0023 | TAKEDA PHARMACEUTICALS AMERICA, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726D0041 | GOLDEN STATE MEDICAL SUPPLY, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0022 | AURINIA PHARMA US INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_IDV_36E79722D0011_3600 · retrieved 2026-09-26.